AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 81 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2022. The put-call ratio across all filers is 1.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,545,000 | -37.5% | 150,000 | 0.0% | 0.36% | -33.1% |
| Q2 2023 | $2,472,000 | +59.4% | 150,000 | -11.8% | 0.54% | +51.7% |
| Q1 2023 | $1,551,250 | +30.4% | 170,000 | 0.0% | 0.36% | +28.5% |
| Q4 2022 | $1,190,000 | +49.7% | 170,000 | +9.0% | 0.28% | +57.4% |
| Q3 2022 | $795,000 | +108.7% | 156,000 | 0.0% | 0.18% | +114.6% |
| Q2 2022 | $381,000 | -61.5% | 156,000 | +7.6% | 0.08% | -57.9% |
| Q1 2022 | $990,000 | -15.5% | 145,000 | 0.0% | 0.20% | -8.9% |
| Q4 2021 | $1,172,000 | -17.5% | 145,000 | 0.0% | 0.21% | -22.7% |
| Q3 2021 | $1,421,000 | +61.3% | 145,000 | +11.5% | 0.28% | +54.7% |
| Q2 2021 | $881,000 | -25.0% | 130,000 | 0.0% | 0.18% | -28.4% |
| Q1 2021 | $1,175,000 | +73.0% | 130,000 | +30.0% | 0.25% | +62.3% |
| Q4 2020 | $679,000 | +124.8% | 100,000 | +66.7% | 0.15% | +120.0% |
| Q3 2020 | $302,000 | – | 60,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |